Related Experiment Video
Updated: Jul 16, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Standardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness
Benjamin Lebwohl1, Christopher Ma2, Stephen M Lagana3
1Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
Developing new celiac disease (CeD) treatments requires standardized clinical trial designs. This study provides consensus recommendations for CeD randomized controlled trials (RCTs), focusing on eligibility and outcome measures.
Area of Science:
- Gastroenterology
- Clinical Trial Design
- Celiac Disease Research
Background:
- Safe and effective pharmacologic treatments for celiac disease (CeD) are needed.
- A lack of consensus exists regarding the optimal design of randomized controlled trials (RCTs) for CeD.
- Standardized approaches are crucial for advancing CeD therapeutic development.
Purpose of the Study:
- To establish consensus on the appropriate design and configuration of RCTs for celiac disease.
- To provide standardized recommendations for key aspects of CeD clinical trials.
- To guide future research in pharmacologic treatments for CeD.
Main Methods:
- A 2-round modified Research and Development/University of California Los Angeles Appropriateness Method study was employed.
- Eighteen expert gastroenterologists and gastrointestinal pathologists voted on statements regarding CeD RCTs.
- Two distinct RCT designs were evaluated: those incorporating a gluten challenge and those assessing reversal of histologic changes.
Main Results:
- Recommendations were established for participant eligibility criteria, including dietary adherence and baseline histology.
- Specific guidance was provided for conducting gluten challenges (e.g., FODMAPs-free) and selecting outcome measures.
- Both histologic and patient-reported outcomes were considered appropriate for evaluating treatment efficacy in CeD trials.
Conclusions:
- Standardized recommendations for CeD clinical trial design, eligibility, and outcome measures have been developed.
- These recommendations aim to improve the consistency and rigor of future RCTs in celiac disease.
- The consensus provides a framework for evaluating novel pharmacologic interventions for CeD.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Crossover Experiments
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.

